Home › Compound Library › Atogepant (Qulipta)

Atogepant (Qulipta)

CGRP Antagonistprescriptionoral · inferred

Small-molecule CGRP receptor antagonist approved for episodic and chronic migraine prevention; 10 mg, 30 mg, or 60 mg once daily. Plasma half-life ~11h. Unlike rimegepant is not dosed acutely. Metabolized by CYP3A4; dose-reduce with strong inhibitors.

Projected serum levels — 60 mg, once daily

Atogepant (Qulipta)
Atogepant (Qulipta) modeled serum levels, 60 mg once daily over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 2 days. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 2
Atogepant (Qulipta) modeled serum levels with a loading dose of 74.7 mg, then 60 mg once daily The first dose is larger so levels approach steady state faster. 0 5 10 15 20 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule

Maintenance schedule: 60 mg once daily (oral).

Loading schedule: 74.7 mg on day 1, then 60 mg once daily — reaching therapeutic levels sooner.

Modeled steady state after ~2 days: peak ≈ 14.7 mg, trough ≈ 3.4 mg body load. Population-based estimate over 15 days for a 60 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
CGRP Antagonist
Route modeled
Oral
Model confidence
inferred
Half-life
11 h
Common dose
60 mg
Suggested maximum
60 mg/day
Reference dose range
30–60 mg (single dose)
Suggested cadence
once daily
Validated against
60 mg oral — Cmax 0.20 mg/L at 2 h

Documented interactions

  • contraindicated
    Carbamazepine (Tegretol) + Atogepant (Qulipta) CYP induction

    Carbamazepine (Tegretol) inducer of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~0.20x

  • contraindicated
    Clarithromycin (Biaxin) + Atogepant (Qulipta) CYP inhibition

    Clarithromycin (Biaxin) mechanism_based of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~10.00x

  • contraindicated
    Dasatinib (Sprycel) + Atogepant (Qulipta) CYP inhibition

    Dasatinib (Sprycel) time_dependent_inhibitor of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~5.00x

  • contraindicated
    Diltiazem + Atogepant (Qulipta) CYP inhibition

    Diltiazem mechanism_based of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~10.00x

  • contraindicated
    Efavirenz (Sustiva) + Atogepant (Qulipta) CYP induction

    Efavirenz (Sustiva) inducer of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~0.12x

  • contraindicated
    Grapefruit (whole fruit) + Atogepant (Qulipta) CYP inhibition

    Grapefruit (whole fruit) mechanism_based of CYP3A4 predicted to change Atogepant (Qulipta) AUC by ~10.00x

Serum checks 94 modeled interaction pairings for atogepant (qulipta) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Single-dose pharmacokinetics and safety of atogepant in participants with hepatic impairment Boinpally R et al. · Clinical Pharmacology in Drug Development, 2021 DOI

    PK study in hepatic impairment informing dose recommendations and characterizing atogepant's ~11h half-life.

  2. Atogepant for the preventive treatment of migraine (ADVANCE) Ailani J et al. · New England Journal of Medicine, 2021 DOI

    ADVANCE phase 3 trial demonstrating atogepant 10/30/60 mg daily significantly reduced monthly migraine days in episodic migraine prevention.

2 published studies referenced in the app, each with a plain-language summary.